Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03257410 · ClinicalTrials.gov registry record · NA
Theranova 400 Dialyzer In End Stage Renal Disease (ESRD) Patients
A NA study, sponsored by Vantive Health.
- Completed
- Registry status
- NA
- Development phase
- 172
- Enrollment target
NCT03257410: Completed NA study, sponsored by Vantive Health.
NCT03257410 is a NA study that has completed, run by Vantive Health. The registered enrollment target is 172 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (88% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03257410, a NA study, has completed, sponsored by Vantive Health.
- COMPLETED
- Registry status
- NA
- Development phase
- 172 participants
- Enrollment target
Study Summary
The study evaluates the efficacy and safety of the Theranova 400 dialyzer compared with Elisio-17 H dialyzer in end stage renal disease patients receiving hemodialysis treatment. Efficacy will be determined by the removal of middle molecules (with different molecular size) from the blood compartment. Safety will be evaluated by maintaining pre-dialysis serum albumin levels and other safety events including laboratory tests and adverse events. Patients will undergo 3 dialysis sessions per week, for 24 weeks.
Primary Outcome
FLC=free light chains
Interventions
- DEVICE Theranova 400 dialyzer
- DEVICE Elisio-17H dialyzer
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 172 participants |
| Start Date | 2017-09-29 |
| Est. Completion | 2018-10-27 |
| Phase | NA |
What the finished NCT03257410 record still lists
NCT03257410 is an interventional study that assigns participants to a tested intervention. The registered 172 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (88% lower).
The record links to 0 conditions, and to 2 interventions - of which Theranova 400 dialyzer is the first listed.
NCT03257410 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03257410 about?
NCT03257410 is a clinical study titled "Theranova 400 Dialyzer In End Stage Renal Disease (ESRD) Patients". The study evaluates the efficacy and safety of the Theranova 400 dialyzer compared with Elisio-17 H dialyzer in end stage renal disease patients receiving hemodialysis treatment. Efficacy will be determined by the removal of middle molecules (with different molecular size) from the blood compartment...
What is the current status of trial NCT03257410?
This trial is currently completed. It is a NA study. The enrollment target is 172 participants. The study started on 2017-09-29. Estimated completion is 2018-10-27.
What interventions are being tested in trial NCT03257410?
The interventions under investigation include: Theranova 400 dialyzer (DEVICE), Elisio-17H dialyzer (DEVICE).
Who is sponsoring clinical trial NCT03257410?
This trial is sponsored by Vantive Health, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03257410's enrollment target sits among peer trials
172 612th of 2000 higher than 1,389 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04801797 · 172 participants · Phase 2
Venetoclax + Azacitidine vs. Induction Chemotherapy in AML
- NCT04867317 · 172 participants · Phase 3
Growth Hormone Replacement Therapy in Veterans With Mild Traumatic Brain Injury (mTBI) and Adult Growth Hormone Deficiency (AGHD)
- NCT05357040 · 172 participants · Phase 2
Antidepressant Effects of Nitrous Oxide
- NCT05587517 · 172 participants · Phase 2
A Clinical Trial of Interventions to Support Family Surrogates of Critically Ill Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI